Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo
Advanced Science · 2026-07 · 13 (38)
DOI: 10.1002/advs.75291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.04.2026. Verfasst von Fernanda V Cabral und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pancreatic Neoplasms, Minocycline, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Overcoming drug resistance in pancreatic ductal adenocarcinoma (PDAC) remains a major challenge due to dense fibrotic stroma, DNA repair–mediated resistance, drug efflux mechanisms, and an immunosuppressive tumor microenvironment (TME). Here, we use photoactivatable multi‐inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA‐approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. PMILs enable light‐triggered PDP followed by IRI release. The reduced Tdp1 combined with PDP and IRI acts synergistically to enhance antitumor activity. In an orthotopic PDAC mouse model, dual priming significantly increased intratumoral IRI accumulation while downregulating Tdp1 and ABCG2, two key mediators of IRI resistance. These effects were augmented by immune activation, including increased CD8 + T‐cell infiltration, reduced regulatory T cells, and M2‐like macrophage population. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long‐term survival (63%). By integrating clinically approved agents with non‐overlapping mechanisms within a light‐activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo‐ and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellman Center For Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Bioengineering, University of Texas at Dallas, Richardson, Texas, USA.
- Fischell Department of Bioengineering, College Park, University of Maryland, Maryland, MD, USA.
- Division of Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID-Profile: Fernanda V Cabral, Girgis Obaid, Huang-Chiao Huang, Tayyaba Hasan
Förderung
- NIBIB NIH HHS
- NIH HHS
- NCI NIH HHS
- National Science Foundation
Zitieren
APA
Cabral, F. V., Quilez-Alburquerque, J., Mooradian, O., Vytheswarran, S., Parshad, B., Obaid, G., Huang, H. C., & Hasan, T. (2026). Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. Advanced Science, 13(38). https://doi.org/10.1002/advs.75291
Vancouver
Cabral FV, Quilez-Alburquerque J, Mooradian O, Vytheswarran S, Parshad B, Obaid G, et al. Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. Advanced Science. 2026;13(38). doi:10.1002/advs.75291
BibTeX
@article{Cabral2026,
author = {Cabral, Fernanda V and Quilez-Alburquerque, Jose and Mooradian, Olivia and Vytheswarran, Shivendran and Parshad, Badri and Obaid, Girgis and Huang, Huang-Chiao and Hasan, Tayyaba},
title = {Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {38},
doi = {10.1002/advs.75291}
}
EUVIMED